Melbourne, Feb 20, 2008 (ABN Newswire) - The Directors of Solagran Limited (ASX: SLA) are pleased to announce the achievement of the last significant milestone in the process of obtaining Manufacturing Licences for both the prescription pharmaceutical Ropren(r) and its active ingredient Bioeffective R.
